Synaptic, Ranbaxy urology deal

SNAP granted Ranbaxy (New Delhi, India) a non-exclusive license to its technology for selectively antagonizing alpha-1a receptors to treat benign prostatic hyperplasia (BHP). SNAP will receive an up-f...